How the body controls Th17 immune cells
Innate mechanisms of regulation of Th17 responses
['FUNDING_R01'] · CINCINNATI CHILDRENS HOSP MED CTR · NIH-11249225
This work looks at how signals between immune cells make Th17 cells ramp up or calm down for people with autoimmune conditions like rheumatoid arthritis, psoriasis, and inflammatory bowel disease.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | CINCINNATI CHILDRENS HOSP MED CTR (nih funded) |
| Locations | 1 site (CINCINNATI, UNITED STATES) |
| Trial ID | NIH-11249225 on ClinicalTrials.gov |
What this research studies
From a patient's view, researchers are following up on discoveries that certain T cells can tell other immune cells to release inflammatory signals without infection. They will use experiments with immune cells in the lab and animal models to map the molecular signals (including TNFα, FasL, caspase-8 and related pathways) that drive IL-1β and Th17 responses. The team aims to find the checkpoints that normally restrain Th17-driven inflammation and what goes wrong in autoimmune disease. Findings could point to new targets for therapies that reduce tissue damage in organs like joints, skin, gut, and kidneys.
Who could benefit from this research
Good fit: Ideal candidates would be people with Th17-associated autoimmune diseases (for example rheumatoid arthritis, psoriasis, multiple sclerosis, or inflammatory bowel disease) who can donate blood or tissue samples or participate in related clinical protocols.
Not a fit: People whose illness is not immune-driven or is caused by infections, metabolic, or purely genetic conditions unrelated to Th17 biology are unlikely to benefit directly from this work.
Why it matters
Potential benefit: If successful, this work could reveal new ways to block harmful Th17-driven inflammation and lead to treatments that better protect organs from autoimmune damage.
How similar studies have performed: Some approved therapies that target TNF or IL-17 already help patients, but this project focuses on earlier immune signals and could identify new, less-tested targets.
Where this research is happening
CINCINNATI, UNITED STATES
- CINCINNATI CHILDRENS HOSP MED CTR — CINCINNATI, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: PASARE, CHANDRASHEKHAR — CINCINNATI CHILDRENS HOSP MED CTR
- Study coordinator: PASARE, CHANDRASHEKHAR
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Autoimmune Diseases